Adamas Pharmaceuticals focuses on therapies to reduce the burden of neurological diseases on patients, caregivers, and society. Co.'s product, GOCOVRI (amantadine) extended-release capsules, is for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Co.'s partnered product, Namzaric® (memantine hydrochloride extended release and donepezil hydrochloride) capsules, are for the treatment of moderate to severe dementia of an Alzheimer's type, marketed in the U.S. by Allergan plc under a license agreement between Co. and Forest Laboratories Holdings Limited, a subsidiary of Allergan plc. The ADMS stock yearly return is shown above.
The yearly return on the ADMS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ADMS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|